Business Paid
Ryvu Therapeutics launches clinical trials of RVU120
17:26
Ryvu Therapeutics has shared progress on the phase I trial of RVU120, planning to initiate the first efficacy-confirming phase II study in Q4 2023. The company is financially secure until Q1 2026. Hendrik Nogai, a board member, expressed confidence in completing RVU120's phase I development in 2023 and initiating phase II, positioning Ryvu as a pioneer in…
This article is for subscribers
Warsaw Business Journal subscribers get the full archive (12,248 articles going back to 1995) and the print edition.
SubscribeOr try Poland A.M. free for 7 days, the daily briefing, or see all plans and prices.
